Venture(US:VEMLY) Xin Lang Cai Jing·2025-12-02 08:57Core Viewpoint - The company, Green Biological Technology Co., Ltd., has submitted its third IPO application for the ChiNext board after two previous unsuccessful attempts, facing multiple challenges including regulatory penalties and issues with information disclosure [3][41]. Company Overview - Green Biological was established in 1999 and has developed a product system comprising three main series: turpentine, cedarwood oil, and fully synthetic products. It is a significant supplier of sandalwood fragrance products in China and one of the largest suppliers of methyl cedar ketone [4][41]. - The company has long-term partnerships with major clients such as Givaudan, International Flavors & Fragrances, and Procter & Gamble, with the top five customers accounting for approximately 43.98% to 40.51% of sales from 2022 to 2025 [5][43]. Financial Performance - The company reported revenues of 5.4 billion, 5.94 billion, and 6.31 billion yuan from 2020 to 2022, with net profits of 644.3 million, 407.4 million, and 681.4 million yuan respectively. The gross profit margins ranged from 20.37% to 26.6% during the same period [56][57]. - For the first half of 2025, the company expects to raise 690 million yuan through its IPO, with plans to invest in expanding production capacity and upgrading facilities [41][34]. IPO Attempts and Challenges - The first IPO attempt in December 2020 was withdrawn within two months due to undisclosed environmental penalties and a significant expected drop in net profit for 2021 [9][11][50]. - The second attempt in June 2023 also faced scrutiny, leading to a withdrawal in September 2024 after two rounds of inquiries from the Shenzhen Stock Exchange regarding compliance and governance issues [56][58]. Governance and Succession - The founder, Lu Wencao, is currently 83 years old, raising concerns about the company's governance and succession planning. His daughter, Lu Wei, has been involved in the company since 2016 and is set to inherit a significant portion of shares [20][58]. Research and Development - The company's R&D expenditure has consistently been below 4% of revenue, which is lower than the industry average. The R&D costs from 2017 to 2025 were reported to be between 2.34% and 3.78% of revenue [25][26]. - There has been a notable increase in personnel costs within R&D, with 2024 showing a 109% increase compared to 2023, raising concerns about the allocation of R&D funds [27][29]. Cash Dividends and Financial Health - Despite ongoing cash dividends, the company has a significant amount of short-term debt and a low level of liquid assets, indicating potential liquidity issues. The total cash dividends from 2018 to 2024 amounted to 249 million yuan, which is 46.98% of the total net profit during that period [31][32][34]. - The company has maintained a high dividend payout ratio, with dividends exceeding net profits in some years, raising questions about its financial sustainability [31][32].